Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2017
Localization of Unknown Primary Site with
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01619865 (Safety & Efficacy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Diagnosis, Staging & Measurement of Response to Treatment in Patients With Somatostatin Receptor Positive Tumors), which is not on this map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety & Efficacy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Diagnosis, Staging & Measurement of Response to Treatment in Patients With Somatostatin Receptor Positive Tumors: Comparison to Octreoscan Plus High-Resolution, Contrast Enhanced CT.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Pooled it
- The Use and Utility of Preoperative Somatostatin Receptor-Based Imaging in Gastroenteropancreatic Neuroendocrine Tumors.Annals of surgical oncology · 2026Article
- Molecular imaging in the diagnostic process of neuroendocrine tumors: a systematic review on unknown primary origin and suspected NETs.EJNMMI reports · 2025Review
- Dual PET Imaging with [Current oncology (Toronto, Ont.) · 2025Article
- Current progress and remaining challenges of peptide-drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?Journal of nanobiotechnology · 2025Review
- The University of Iowa Neuroendocrine Tumor Clinic.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025Article
- Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives.Cancers · 2024Review
- Factors Affecting Survival Outcomes in Neuroendocrine Tumor of the Appendix over the Past Two Decades.Diseases (Basel, Switzerland) · 2024Article
- Managing end-stage carcinoid heart disease: A case report and literature review.World journal of gastrointestinal oncology · 2024Article
- Two cases of pancreatic tuberculosis in immunocompetent individuals presenting as diabetes mellitus: An overview of clinical features, diagnosis and management.Qatar medical journal · 2024Article
- Prognostic Implications of PET-Derived Tumor Volume and Uptake in Patients with Neuroendocrine Tumors.Cancers · 2023Review
- Analysis of surgical treatment of appendix neuroendocrine neoplasms-17 years of single-center experience.World journal of surgical oncology · 2023Article
- Abdominal Aortic Aneurysm and PET/CT: From Molecular Mechanisms to Potential Molecular Imaging Targets.Reviews in cardiovascular medicine · 2023Review
- Review
- An abdominal wall neuroendocrine tumor of unknown primary origin: A case report and review of the literature.Cancer reports (Hoboken, N.J.) · 2022Review
- An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.World journal of gastroenterology · 2022Review
- Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment.Pharmaceutics · 2020Article
- Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients.Oncotarget · 2020Article
- Nuclear Imaging of Neuroendocrine Tumors.Surgical oncology clinics of North America · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Localization of the site of the unknown primary tumor is critical for surgical treatment of patients presenting with neuroendocrine tumor (NET) with metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.